Paola Nisticò

List of Publications by Year
in descending order

63	2,881	218677	175258
papers	citations	26	52
		h-index	g-index

69	69	69	4252
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Epithelial-Mesenchymal Transition: General Principles and Pathological Relevance with Special Emphasis on the Role of Matrix Metalloproteinases. Cold Spring Harbor Perspectives in Biology, 2012, 4, a011908-a011908.	5.5	231
2	Cross-reactivity between tumor MHC class I–restricted antigens and an enterococcal bacteriophage. Science, 2020, 369, 936-942.	12.6	217
3	α6β4 and α6β1 Integrins Associate with ErbB-2 in Human Carcinoma Cell Lines. Experimental Cell Research, 1997, 236, 76-85.	2.6	201
4	Relevance of immune cell and tumor microenvironment imaging in the new era of immunotherapy. Journal of Experimental and Clinical Cancer Research, 2020, 39, 89.	8.6	157
5	Circulating Autoantibodies to Phosphorylated α-Enolase are a Hallmark of Pancreatic Cancer. Journal of Proteome Research, 2011, 10, 105-112.	3.7	119
6	An integrated humoral and cellular response is elicited in pancreatic cancer by α–enolase, a novel pancreatic ductal adenocarcinoma–associated antigen. International Journal of Cancer, 2009, 125, 639-648.	5.1	115
7	Splicing program of human MENA produces a previously undescribed isoform associated with invasive, mesenchymal-like breast tumors. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 19280-19285.	7.1	112
8	Identification of invasion specific splice variants of the cytoskeletal protein Mena present in mammary tumor cells during invasion inÂvivo. Clinical and Experimental Metastasis, 2009, 26, 153-159.	3.3	107
9	Chemotherapy enhances vaccine–induced antitumor immunity in melanoma patients. International Journal of Cancer, 2009, 124, 130-139.	5.1	103
10	Alpha-enolase (ENO1) controls alpha v/beta 3 integrin expression and regulates pancreatic cancer adhesion, invasion, and metastasis. Journal of Hematology and Oncology, 2017, 10, 16.	17.0	101
11	Polyphenols: Immunomodulatory and Therapeutic Implication in Colorectal Cancer. Frontiers in Immunology, 2019, 10, 729.	4.8	101
12	Autoantibody Signature in Human Ductal Pancreatic Adenocarcinoma. Journal of Proteome Research, 2007, 6, 4025-4031.	3.7	88
13	Molecular Cloning of hMena (ENAH) and Its Splice Variant hMena+11a: Epidermal Growth Factor Increases Their Expression and Stimulates hMena+11a Phosphorylation in Breast Cancer Cell Lines. Cancer Research, 2007, 67, 2657-2665.	0.9	80
14	Human mena protein, a serex-defined antigen overexpressed in breast cancer eliciting both humoral and CD8+T-cell immune response. International Journal of Cancer, 2004, 109, 909-918.	5.1	78
15	3D models in the new era of immune oncology: focus on T cells, CAF and ECM. Journal of Experimental and Clinical Cancer Research, 2019, 38, 117.	8.6	78
16	The Cytoskeleton Regulatory Protein hMena (ENAH) Is Overexpressed in Human Benign Breast Lesions with High Risk of Transformation and Human Epidermal Growth Factor Receptor-2–Positive/Hormonal Receptor–Negative Tumors. Clinical Cancer Research, 2006, 12, 1470-1478.	7.0	73
17	Deciphering the loop of epithelial-mesenchymal transition, inflammatory cytokines and cancer immunoediting. Cytokine and Growth Factor Reviews, 2017, 36, 67-77.	7.2	71
18	Fibronectin as a multiregulatory molecule crucial in tumor matrisome: from structural and functional features to clinical practice in oncology. Journal of Experimental and Clinical Cancer Research, 2021, 40, 102.	8.6	64

#	Article	IF	Citations
19	Human Mena+11a Isoform Serves as a Marker of Epithelial Phenotype and Sensitivity to Epidermal Growth Factor Receptor Inhibition in Human Pancreatic Cancer Cell Lines. Clinical Cancer Research, 2008, 14, 4943-4950.	7.0	63
20	Mutant p53 gains new function in promoting inflammatory signals by repression of the secreted interleukin-1 receptor antagonist. Oncogene, 2015, 34, 2493-2504.	5.9	59
21	Dacarbazine Treatment before Peptide Vaccination Enlarges T-Cell Repertoire Diversity of Melan-Aâ€"Specific, Tumor-Reactive CTL in Melanoma Patients. Cancer Research, 2010, 70, 7084-7092.	0.9	57
22	Î²1 and Î²4 integrins: from breast development to clinical practice. Breast Cancer Research, 2014, 16, 459.	5.0	57
23	Autoantibodies to Ezrin are an early sign of pancreatic cancer in humans and in genetically engineered mouse models. Journal of Hematology and Oncology, 2013, 6, 67.	17.0	42
24	Combination of chemotherapy and PD-1 blockade induces T cell responses to tumor non-mutated neoantigens. Communications Biology, 2020, 3, 85.	4.4	36
25	Identification of a public CDR3 motif and a biased utilization of T-cell receptor V beta and J beta chains in HLA-A2/Melan-A-specific T-cell clonotypes of melanoma patients. Journal of Translational Medicine, 2009, 7, 21.	4.4	32
26	Prognostic impact of alternative splicing-derived hMENA isoforms in resected, node-negative, non-small-cell lung cancer. Oncotarget, 2014, 5, 11054-11063.	1.8	32
27	Polyfunctional Melan-A-specific tumor-reactive CD8+ T cells elicited by dacarbazine treatment before peptide-vaccination depends on AKT activation sustained by ICOS. OncoImmunology, 2016, 5, e1114203.	4.6	25
28	Modulation of the antigenic phenotype of early-passage human melanoma cells derived from multiple autologous metastases by recombinant human leukocyte, fibroblast and immune interferon. International Journal of Cancer, 1990, 46, 539-545.	5.1	24
29	Molecular and Genetic Bases of Pancreatic Cancer. Current Drug Targets, 2012, 13, 731-743.	2.1	24
30	The pattern of hMENA isoforms is regulated by TGF-Î²1 in pancreatic cancer and may predict patient outcome. OncoImmunology, 2016, 5, e1221556.	4.6	23
31	IL-18 receptor marks functional CD8+ T cells in non-small cell lung cancer. OncoImmunology, 2017, 6, e1328337.	4.6	23
32	The Cooperation between hMena Overexpression and HER2 Signalling in Breast Cancer. PLoS ONE, 2010, 5, e15852.	2.5	23
33	Imaging laser diffractometer for traceable grating pitch calibration. Measurement Science and Technology, 2007, 18, 375-383.	2.6	22
34	hMENA is a key regulator in endothelin-1/Î²-arrestin1â€"induced invadopodial function and metastatic process. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 3132-3137.	7.1	21
35	Gene transfer by retrovirus-derived shuttle vectors in the generation of murine bispecific monoclonal antibodies.. Proceedings of the National Academy of Sciences of the United States of America, 1990, 87, 2941-2945.	7.1	20
36	The actin modulator hMENA regulates GAS6â€"AXL axis and proâ€"tumor cancer/stromal cell cooperation. EMBO Reports, 2020, 21, e50078.	4.5	20

#	Article	IF	Citations
37	hMENA isoforms impact NSCLC patient outcome through fibronectin/Î²1 integrin axis. Oncogene, 2018, 37, 5605-5617.	5.9	17
38	Combinations of immuno-checkpoint inhibitors predictive biomarkers only marginally improve their individual accuracy. Journal of Translational Medicine, 2019, 17, 131.	4.4	17
39	Actin Cytoskeleton and Regulation of TGFÎ² Signaling: Exploring Their Links. Biomolecules, 2021, 11, 336.	4.0	17
40	Melan-A/MART-1 Antigen Expression in Cutaneous and Ocular Melanomas. Journal of Immunotherapy, 1997, 20, 466-469.	2.4	15
41	Biological mechanisms linked to inflammation in cancer: Discovery of tumor microenvironment-related biomarkers and their clinical application in solid tumors. International Journal of Biological Markers, 2020, 35, 8-11.	1.8	15
42	Cell retargeting by bispecific monoclonal antibodies. Evidence of bypass of intratumor susceptibility to cell lysis in human melanoma.. Journal of Clinical Investigation, 1992, 90, 1093-1099.	8.2	15
43	Low Frequency of ErbB-2 Proto-oncogene Overexpression in Human Leukocyte Antigen-A2-Positive Breast Cancer Patients. Journal of the National Cancer Institute, 1997, 89, 319-321.	6.3	13
44	hMENA11a contributes to HER3-mediated resistance to PI3K inhibitors in HER2-overexpressing breast cancer cells. Oncogene, 2016, 35, 887-896.	5.9	13
45	Host immunosurveillance contributes to the control of erbB-2 overexpression in HLA-A2-breast-cancer patients. International Journal of Cancer, 1999, 84, 598-603.	5.1	12
46	Generation and characterization of two human alpha/beta T cell clones. Recognizing autologous breast tumor cells through an HLA- and TCR/CD3-independent pathway.. Journal of Clinical Investigation, 1994, 94, 1426-1431.	8.2	9
47	MHC-Peptide Binding. Journal of Immunotherapy, 1997, 20, 431-436.	2.4	8
48	Multicentre Harmonisation of a Six-Colour Flow Cytometry Panel for NaÃ¯ve/Memory T Cell Immunomonitoring. Journal of Immunology Research, 2020, 2020, 1-15.	2.2	8
49	Antigen-specificity and DTIC before peptide-vaccination differently shape immune-checkpoint expression pattern, anti-tumor functionality and TCR repertoire in melanoma patients. OncoImmunology, 2018, 7, e1465163.	4.6	6
50	Clinical and Immunological Outcomes in High-Risk Resected Melanoma Patients Receiving Peptide-Based Vaccination and Interferon Alpha, With or Without Dacarbazine Preconditioning: A Phase II Study. Frontiers in Oncology, 2020, 10, 202.	2.8	6
51	Mesenchymal traits at the convergence of tumor-intrinsic and -extrinsic mechanisms of resistance to immune checkpoint blockers. Emerging Topics in Life Sciences, 2017, 1, 471-486.	2.6	5
52	hMENA11a, a hMENA isoform sending survival signals. Molecular and Cellular Oncology, 2016, 3, e1083648.	0.7	2
53	Actin Cytoskeleton Dynamics and Type I IFN-Mediated Immune Response: A Dangerous Liaison in Cancer?. Biology, 2021, 10, 913.	2.8	2
54	Abstract 4316: hMENA11acontributes to HER3-mediated resistance to PI3K inhibitors in HER2 overexpressing breast cancer cells. , 2015, , .		1

#	Article	IF	Citations
55	Prognostic impact of the cytoskeleton regulatory protein hMena in resected node-negative non-small cell lung cancer (NSCLC): A clinical-biological risk stratification model.. Journal of Clinical Oncology, 2010, 28, 7027-7027.	1.6	1
56	Polyclonal Antibodies Against gp185HER2 Peptides: Their Putative Role in the Identification of a Particular HER2 Status in Patients With Breast Cancer. Journal of Immunotherapy, 2001, 24, 221-231.	2.4	0
57	hMENA splicing program impacts the clinical outcome of early stage lung cancer patients. How and why?. Journal of Translational Medicine, 2014, 12, .	4.4	0
58	A cytofluorimetric assay to evaluate T cell polyfunctionality. Methods in Enzymology, 2020, 631, 61-76.	1.0	0
59	Abstract 4406: Clinical efficacious combined chemo/immunotherapy differently activates AKT pathway and functionality of gp100 and Melan-A specific T cell clones. , 2012, , .		0
60	Abstract 1035: hMENA splicing program and TGF-Î²1-mediated EMT in pancreatic cancer. , 2014, , .		0
61	Abstract A60: The hMENA Splicing Program: An important regulator of TGFÎ²1-driven EMT and invasiveness in pancreatic cancer. , 2015, , .		0
62	Abstract A003: Polyfunctional antitumor CD8 T cells obtained from a broad repertoire elicited by chemo-immunotherapy and preventing melanoma relapse depends on the activation of an AKT pathway sustained by ICOS. , 2016, , .		0
63	Abstract A113: The pattern of hMENA isoforms is regulated by TGF-Î²1 in pancreatic cancer and may predict patient outcome. , 2016, , .		0